Piperazine → HCID 21891585, Verbindung
Reaktionsgleichung
[CH3:1][N:2]1[C:10]2[C:5](=[C:6]([O:15][CH3:16])[C:7]([O:13][CH3:14])=[C:8]([O:11][CH3:12])[CH:9]=2)[CH:4]=[C:3]1[C:17]([OH:19])=O.[NH:20]1[CH2:25][CH2:24][NH:23][CH2:22][CH2:21]1>>[CH3:1][N:2]1[C:10]2[C:5](=[C:6]([O:15][CH3:16])[C:7]([O:13][CH3:14])=[C:8]([O:11][CH3:12])[CH:9]=2)[CH:4]=[C:3]1[C:17]([N:20]1[CH2:25][CH2:24][N:23]([C:17]([C:3]2[N:2]([CH3:1])[C:10]3[C:5]([CH:4]=2)=[C:6]([O:15][CH3:16])[C:7]([O:13][CH3:14])=[C:8]([O:11][CH3:12])[CH:9]=3)=[O:19])[CH2:22][CH2:21]1)=[O:19]Komponenten
3
Versuchsvorschrift
N-Methyl-4,5,6-trimethoxyindole-2-carboxylic acid (200 mg) and piperazine (35 mg) were reacted in the same manner as in Preparation Example 37 to obtain the title compound.
Quellen und Nachweise
- ORD-Eintrag
- ord-719b36be50464e98b6d460cfb6429f6f
- Quelldatensatz
- uspto-grants-2006_11
- Patentnummer
- US07135473B2
Notizen zur Reaktion
Wird geladen…